# DexCom Inc. (DXCM) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $87.90, market value $33.2 billion.

## Valuation
- **P/E (trailing): 34.7×** (5-yr avg 114.7×, 3-yr avg 60.7×). DexCom Inc. trades at 34.7× trailing earnings, well below its own five-year average of 114.7×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 28.1×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.60**. A PEG of 0.60 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 6.7×**. Each dollar of revenue is priced at 6.7×.
- **Price / book: 12.7×**. The shares trade at 12.7× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 23.0×**. Enterprise value is 23.0× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 4.2%** (5-yr avg 1.5%). Free cash flow equals 4.2% of the market value, above its five-year average of 1.5%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 2.9%**. The inverse of the P/E: 2.9% of the price is earned each year.

## Profitability
- **Gross margin: 62.5%**. DexCom Inc. keeps 62.5% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 22.9%**. 22.9% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 17.9%**. 17.9% of each dollar of sales reaches the bottom line.
- **Return on equity: 30.5%**. 30.5% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 49.1%**. Return on all capital, debt included, is 49.1%: comfortably above what that capital costs.
- **Return on assets: 15.8%**. Each dollar of assets produces 15.8% of profit.

## Growth
- **Revenue growth (1 yr): 15.6%** (3-yr 17.0%/yr, 5-yr 19.3%/yr). Revenue grew 15.6% over the last year, against 19.3% a year compounded over five years.
- **EPS growth (1 yr): 47.2%** (3-yr 36.6%/yr, 5-yr 9.5%/yr). Earnings per share rose 47.2%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 52.3%/yr**. Free cash flow has compounded at 52.3% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. DexCom Inc. holds more cash than debt.
- **Current ratio: 1.88** (quick 1.88). Current assets cover the next year's liabilities 1.88 times.
- **Altman Z-score: 7.71**. A Z-score of 7.71 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend: none**. DexCom Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (25 analysts). 25 analysts cover DexCom Inc.; the consensus is strong_buy, with an average price target of $94.12 (+7% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 8.8%** (YTD 32.4%, 3-mo 20.6%). The shares are up 8.8% over twelve months including dividends.
- **From 52-week high: -5.1%** (62.4% above the low). Trading 5% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 53**. An RSI of 53 is neutral.
- **Beta (1 yr): 0.75** (volatility 41%). Beta of 0.75 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=DXCM · Page: https://foliofundamentals.com/stocks/dxcm

Not investment advice.